Troculeucel

NKGen Biotech (NKGN) secured $2M from a Japanese investor to regain compliance after its parent company’s bankruptcy. Shares move to OTC Expert Market temporarily before uplisting to OTCQB and eventually Nasdaq/NYSE American. The funding supports the development of troculeucel, an NK cell therapy for neurodegenerative diseases moving forward in Phase 2 trials. NKGen also plans to acquire a majority stake in NKMax, consolidating key IP rights across Asia.